Type 1 Diabetes Mellitus
Pipeline by Development Stage
Drug Modality Breakdown
Type 1 Diabetes Mellitus is a $5.8B Part D market dominated by insulin analogs, with mature treatment patterns but emerging disease-modifying opportunities.
Key Trends
- Insulin analogs command 69-77% of market; basal-bolus and premixed formulations remain standard of care
- Disease-modifying agents (e.g., teplizumab) represent early-stage competition in prevention/progression
- High trial activity (242 trials) suggests pipeline innovation in delivery systems, immunotherapy, and adjunctive therapies
Career Verdict
Solid career choice for specialists seeking stability with emerging upside; insulin franchise is established but innovation pipeline offers differentiation opportunities.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ADMELOG (insulin lispro) | Sanofi | $1M | — | PEAK | Stable |
Drug Class Breakdown
established maintenance, delivery innovation driving incremental growth
adjunctive to insulin therapy
stable, mature class
growing adjunctive demand
early-stage; teplizumab (TZIELD) recently approved, high unmet need
Career Outlook
StableType 1 Diabetes remains a stable, high-value market with mature insulin sales and emerging opportunities in disease-modifying therapies, digital health, and device integration. Commercial and engineering roles dominate, while clinical and regulatory roles support growing pipeline activity (242 trials). Career stability is high, but growth is incremental unless disease-modifying agents (e.g., teplizumab) achieve rapid adoption.
Breaking In
Target commercial or engineering roles at Sanofi, Eli Lilly, or device-focused companies; prior diabetes care, insulin pharmacology, or device design experience accelerates progression.
For Experienced Professionals
Reposition into disease-modifying pipeline roles or digital health strategy to capture next-wave growth; insulin generics/biosimilar pressure favors those moving into innovation-led positions rather than commoditized sales.
In-Demand Skills
Best For
Hiring Landscape
Type 1 Diabetes disease area supports 5,985 jobs across 10 companies, with Sanofi as dominant employer (1,121 jobs). Hiring concentrated in Commercial (1,033 jobs, avg $266K) and Engineering (690 jobs, avg $201K), reflecting product portfolio scale and device/delivery innovation focus. Salary ranges $133K–$266K, offering competitive compensation for insulin delivery and diabetes technology expertise.
By Department
Strong commercial and engineering demand reflects mature insulin market and device/digital health growth; R&D hiring modest but stable, signaling ongoing innovation in delivery systems.
On Market (7)
Approved therapies currently available
Competitive Landscape
65 companies ranked by most advanced pipeline stage
+35 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 11,000 patients across 50 trials
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
Effect of CSII and CGM on Progression of Late Diabetic Complications
Pizza-Salami Study in Children and Adolescents With Type 1 Diabetes
This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety
Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes
Effectiveness Study of the Guardian RT in Type 1 Diabetics
Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
A Study of LY900014 in Participants With Type 1 Diabetes
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
Islet Transplantation in Type 1 Diabetes
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
The Bihormonal iLet Bionic Pancreas Feasibility Study
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)
Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)
Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)
Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects
Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus
Islet Cell Transplant for Type 1 Diabetes
A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM)
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus
LEA29Y (Belatacept) Emory Edmonton Protocol
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
B-Lymphocyte Immunotherapy in Islet Transplantation
Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
Rituximab in New Onset Type 1 Diabetes
Nutritional Prevention Pilot Trial for Type 1 Diabetes
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
Related Jobs in Metabolic Diseases
Trade Analytics Senior Manager
Senior Director, Head of Technical Services, T1D CT Mfg Ops
Senior Director, Head of Quality Control, T1D Mfg Ops
Director, Commercial Supply Chain
Director, Stem Cell Research
Executive Director, Regulatory Strategy, Cell & Gene Therapy
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.